Can a new immune cell therapy outsmart resistant blood cancers?
NCT ID NCT07771361
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This Phase 2 trial is testing an experimental therapy called LMY-920, which uses a patient's own immune cells (T cells) engineered to recognize and attack cancer cells through a protein called BAFF. The study aims to see if this treatment can shrink tumors or eliminate signs of cancer in people with non-Hodgkin lymphoma or multiple myeloma that has returned or not responded to previous treatments. Participants will receive a single infusion of these modified cells, and researchers will monitor for side effects and how well the therapy works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BAFF CAR-T cells (LMY-920), an experimental cell therapy made from a patient's own immune cells
- What this could lead to
- If successful, this could offer a new treatment option for people with blood cancers that have stopped responding to standard therapies, potentially leading to long-term remission.
- What could go wrong
- This is an early-stage trial, so the treatment may not work for everyone and could cause serious side effects. More research is needed to confirm its safety and effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tropical tea shrink blood cancers?
- Can a new pill shrink Hard-to-Treat tumors?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?